Curated News
By: NewsRamp Editorial Staff
November 11, 2025

NanoViricides Secures $6M Funding for Antiviral Drug Development

Discuss on Substack
Original Source

TLDR

  • NanoViricides secured $6 million in funding, providing capital advantage to advance its broad-spectrum antiviral drug pipeline ahead of competitors.
  • NanoViricides raised approximately $6 million through a registered direct offering of 3.57 million shares at $1.68 each with attached warrants exercisable at higher prices.
  • This funding supports NanoViricides' development of antiviral treatments that could improve global health by combating respiratory viruses and other infectious diseases.
  • NanoViricides is developing nanomedicine treatments for multiple viruses including RSV, COVID, influenza, and shingles using innovative nanotechnology platforms.

Impact - Why it Matters

This funding development matters because NanoViricides represents a promising approach to addressing the global need for effective antiviral treatments. With viral diseases continuing to pose significant public health threats—from seasonal influenza to emerging pathogens—the advancement of broad-spectrum antiviral technologies could revolutionize how we combat infectious diseases. The company's nanoviricide platform offers potential advantages over traditional antiviral approaches, potentially providing more effective treatments with fewer side effects. For investors, this financing demonstrates continued institutional confidence in the company's technology and development pipeline. For the broader public, successful development of these treatments could mean faster recovery times, reduced hospitalization rates, and better preparedness for future viral outbreaks. The progress of companies like NanoViricides is crucial for building a more resilient global healthcare infrastructure capable of responding to both current and emerging viral threats.

Summary

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biotechnology company, has secured significant funding through a strategic financing arrangement with a healthcare institutional investor. The company announced a registered direct offering involving the purchase of 3,571,429 shares of common stock at $1.68 per share, generating expected gross proceeds of approximately $6 million before expenses. In a concurrent private placement, NanoViricides will issue Series A and Series B warrants, each allowing for the purchase of up to 3,571,429 additional shares with exercise prices of $1.75 and $2.00 per share respectively. The Series A warrants become exercisable six months after issuance and expire in two years, while the Series B warrants have the same exercise commencement but extend for 5.5 years. A.G.P./Alliance Global Partners is serving as the sole placement agent for this transaction, which is expected to close around November 12, 2025, pending customary conditions. The proceeds are designated for working capital and general corporate purposes, supporting the company's ongoing development efforts.

NanoViricides operates as a clinical-stage company developing broad-spectrum antiviral nanomedicines through its innovative nanoviricide technology platform. The company's business model relies on licensing technology from TheraCour Pharma, Inc. for specific antiviral applications, with exclusive, sub-licensable field licenses for numerous viral diseases. Their lead drug candidate, NV-387, represents a broad-spectrum antiviral planned for development against RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Another advanced candidate, NV-HHV-1, targets Shingles treatment. The company is currently focused on advancing NV-387 into Phase II human clinical trials while maintaining a diverse pipeline that includes potential treatments for oral and genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company's technology platform and programs are based on the TheraCour nanomedicine technology, which NanoViricides holds perpetual licenses for across multiple viral disease categories.

The financing announcement was distributed through the InvestorBrandNetwork, which serves as a specialized communications platform within the Dynamic Brand Portfolio at IBN. This network provides advanced wire-grade press release syndication for private and public companies, offering access to extensive distribution channels including article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution to millions of followers, and comprehensive corporate communications solutions. The full press release detailing NanoViricides' financing activities and corporate updates can be accessed through their dedicated newsroom, providing investors and stakeholders with the latest developments regarding the company's progress in antiviral drug development and financial positioning.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Secures $6M Funding for Antiviral Drug Development

blockchain registration record for this content.